Peer-Reviewed Publications

Over the last 10 years, Creative Biolabs has becoming a leader of recombinant antibody (rAb) discovery and manufacturing, providing high quality service to customers in academia and industry fields. Our products and services have been used extensively by scientists all over the world to accelerate their life science research. Here, we present a collection of representative citations.

For your convenience, we have grouped these patents & articles into the following categories:

SECTION 1: Therapeutic Antibodies
SECTION 2: Hi-Affi™ Recombinant Antibodies
SECTION 3: Single Domain Antibodies

SECTION 1: Therapeutic Antibodies[Top]

Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer a full range of therapeutic antibodies currently available for research of a wide variety of diseases.

• Sautto, Giuseppe A., et al. "A Computationally Optimized Broadly Reactive Antigen Subtype–Specific Influenza Vaccine Strategy Elicits Unique Potent Broadly Neutralizing Antibodies against Hemagglutinin." The Journal of Immunology (2019).

This paper described a computationally optimized broadly reactive antigens (COBRA) targeting influenza virus H1 elicit a broad cross-reactive and cross-neutralizing antibody response against multiple H1N1 viral strains. The anti-influenza A hemagglutinin therapeutic antibody Diridavumab (CR6261), FI6, and F10 were obtained from Creative Biolabs.

• Abstract Supplement 2019 ACR/ARP Annual Meeting. Arthritis Rheumatol, 71: 1-5420 (2019), doi:10.1002/art.41108.

This paper mentioned that in two reports titled respectively with "ALPN- 101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Associated with Sjögren’s Syndrome" and "ALPN- 101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Underlying Rheumatoid and Psoriatic Arthritis", which described that the immunosuppressive efficacy of dual CD28/ICOS antagonist ALPN-101 is superior to CD28 or ICOS costimulatory pathway inhibitors, and ALPN-101 may significantly improve upon the clinical efficacy of currently approved therapeutics like abatacept for treatment of inflammatory diseases, the anti-ICOS antibody prezalumab was obtained from Creative Biolabs.

• Vredevoogd, David W., et al. "Augmenting immunotherapy impact by lowering tumor TNF cytotoxicity threshold." Cell 178.3 (2019): 585-599.

This paper suggests that selective reduction of the TNF cytotoxicity threshold increases the susceptibility of tumors to immunotherapy. The enavatuzumab was obtained from Creative Biolabs.

• Kvorjak, Michael, et al. "Crosstalk between colon cells and macrophages increases ST6GALNAC1 and MUC1-sTn expression in ulcerative colitis and colitis-associated colon cancer." Cancer Immunology Research (2019).

The authors demonstrated that IL-13 promoted phosphorylation of STAT6 to activate transcription of ST6GALNAC1, and revealed a novel cellular cross-talk between colon cells and macrophages within the inflamed and malignant colon that contributes to the pathogenesis of ulcerative colitis (UC) and colitis-associated colon cancer (CACC). The anti-human MUC1 therapeutic antibody (5E5) was obtained from Creative Biolabs.

• Bayat, Behnaz, et al. "Current Anti-HPA-1a Standard Antibodies React with the β3 Integrin Subunit but not with αIIbβ3 and αvβ3 Complexes." Thrombosis and haemostasis 119.11 (2019): 1807-1815.

This paper mentioned that current anti- human platelet antigen 1a (HPA-1a) standard material contains only the anti-β3 subtype. The absence of anti-αvβ3 makes National Institute for Biological Standards and Control (NIBSC) 03/152 less suitable as standard to predict the severity of fetal/neonatal alloimmune thrombocytopenia (FNAIT). The therapeutic antibody etaracizumab (humanized murine monoclonal antibody LM609) targeting the αvβ3 complex was obtained from Creative Biolabs.

• Navone, Nora M., and Arul Chinnaiyan. Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer. The University of Texas Houston United States, 2018.

This paper suggests that fibroblast growth factor receptor 1 (FGFR1) alpha and beta activate different genes and pathways in advanced prostate cancer (PCa) cells, thus conferring different phenotypes. The FGFR1 isoform-specific antibodies used were developed in collaboration with Creative Biolabs.

• Nanki, Kosaku, et al. "Divergent routes toward Wnt and R-spondin niche independency during human gastric carcinogenesis." Cell 174.4 (2018): 856-869.

The authors demonstrated that multifaceted genetic abnormalities render human gastric cancers (GCs) independent of the stem cell niche and highlighted the validity of the genotype-phenotype screening strategy in gaining deeper understanding of human cancers. The anti-pan Frizzled therapeutic antibody was obtained from Creative Biolabs.

• Bill, Marius, et al. "EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia." Clinical Cancer Research (2019).

The results in this paper demonstrated that epidermal growth factor-like domain 7 (EGFL7) contributes to NOTCH silencing in acute myeloid leukemia (AML) by antagonizing canonical NOTCH ligand binding, and supported the use of EGFL7 as a novel therapeutic target in AML. The parsatumumab was obtained from Creative Biolabs.

• Wu, Yongzhong, et al. "IL-4 and IL-17A Cooperatively Promote Hydrogen Peroxide Production, Oxidative DNA Damage, and Upregulation of Dual Oxidase 2 in Human Colon and Pancreatic Cancer Cells." The Journal of Immunology 203.9 (2019): 2532-2544.

The data in this research suggest a functional association between dual oxidase 2 (DUOX2) -mediated H₂O₂ production and induced DNA damage in gastrointestinal malignancies. The anti-human DUOX antibody, which reacts with both DUOX1 and DUOX2 was developed by Creative Biolabs.

• Nouadje, Georges, and Thierry Ligneel. "Improved immunofixation electrophoresis method with target component on-gel immunodisplacement." U.S. Patent Application No. 16/320,521.

This patent mentioned the trastuzumab, bevacizumab, and anti-bevacizumab monoclonal antibody were obtained from Creative Biolabs.

• Belkaya, Serkan, et al. "Inherited IL-18BP deficiency in human fulminant viral hepatitis." Journal of Experimental Medicine (2019): jem-20190669.

The findings in this paper provide proof-of-principle that fulminant viral hepatitis (FVH) can be caused by single-gene inborn errors that selectively disrupt liver-specific immunity, and also show that human IL-18 is toxic to the liver and that IL-18BP is its antidote. The mouse anti-HAV VP1 therapeutic antibody (K2-4F2) was obtained from Creative Biolabs.

• Linder, Vincent. "Multiplex assays for evaluating prostate cancer status." U.S. Patent Application No. 16/053,849.

This patent mentioned the scFv fragment, Fab fragment, and intact forms of anti-human kallikrein-2 therapeutic antibody were obtained from Creative Biolabs.

• Chen, Wu, et al. "Performance of Optimized Wide Pore Superficially Porous Particles for Separation of Proteins and Immunoglobulin G Antibodies." Journal of chromatographic science 56.5 (2018): 416-424.

The results in this paper showed that the superficially porous particles (SPPs) containing larger pore size gave better chromatographic performance. The humanized recombinant antibody trastuzumab was obtained from Creative Biolabs.

• Proceedings of the World Molecular Imaging Congress 2019, Montreal Quebec, Canada September 4-7, 2019: Late-Breaking Abstracts. Mol Imaging Biol (2019) 21(Suppl 1): 167.

This paper mentioned that in a report titled with Radiosynthesis and Preclinical PET Evaluation of 89Zr-DFO-Ibalizumab in Healthy Non-Human Primates in which data showed that [89Zr]-DFO-Ibalizumab represents a new modality that may be useful for imaging CD4+ T cells in vivo, the ibalizumab was obtained from Creative Biolabs.

• Lu, Xinmiao, et al. "Radiolabeling and biological evaluation of 125 I-Necitumumab for EGFR-targeted SPECT imaging." Journal of Radioanalytical and Nuclear Chemistry (2019): 1-7.

In this paper the authors found that considered that ¹²⁵I-Necitumumab was not suitable for epidermal growth factor receptor (EGFR)-targeted non-small cell lung cancer (NSCLC) SPECT imaging. The necitumumab was obtained from Creative Biolabs.

• Siu, Kam-Leung, et al. "Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC." The FASEB Journal (2019): fj-201802418R.

This paper reveals a new mechanism by which severe acute respiratory syndrome coronavirus (SARS-CoV) open reading frame 3a (ORF3a) protein activates NF-kB and the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of p105 and caspase recruitment domain (ASC). The canakinumab which blocks IL-1b was obtained from Creative Biolabs.

• Park, Jong-Sung, et al. "Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma." Nature communications 10.1 (2019): 1128.

The authors found that TNF-related apoptosis-inducing ligand (TRAIL) pathway plays a critical role in tissue remodeling and targeting upregulated DR5 in α-smooth muscle actin (α-SMA)+ expressing myofibroblasts (MFBs) is a viable therapy for fibrosis in scleroderma. The mapatumumab, and conatumumab were obtained from Creative Biolabs.

• Limbocker, Ryan, et al. "Trodusquemine enhances Aβ 42 aggregation but suppresses its toxicity by displacing oligomers from cell membranes." Nature communications 10.1 (2019): 225.

The authors found that trodusquemine enhances the rate of aggregation by promoting monomer-dependent secondary nucleation, but significantly reduces the toxicity of the resulting oligomers to neuroblastoma cells by inhibiting their binding to the cellular membranes. The anti-ADDLs therapeutic antibody which blocks IL-1b was obtained from Creative Biolabs.

• Schiffmann, Lars Mortimer, et al. "Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer." British journal of cancer 120.1 (2019): 69.

This research identified CD177+ tumor neutrophil infiltration as an adverse prognostic factor for bevacizumab treatment, and demonstrated that a novel anti-VEGF/anti-Ang2 compound (BI-880) can overcome resistance to VEGF inhibition in experimental tumor models. The anti-VEGF therapeutic antibody (B20-4.1.1) was obtained from Creative Biolabs.

SECTION 2: Hi-Affi™ Recombinant Antibodies [Top]

Creative Biolabs is a pioneer of recombinant antibody discovery and manufacturing, and have developed proprietary procedures for Hi-Affi™ recombinant antibody production, providing the most comprehensive list of recombinant antibody products in the world.

• Park, Mi Ae, et al. "Activation of the arterial program drives development of definitive hemogenic endothelium with lymphoid potential." Cell reports 23.8 (2018): 2467-2481.

The findings in this paper provide an innovative strategy to aid in the generation of definitive lymphomyeloid progenitors and lymphoid cells from human pluripotent stem cells (hPSCs) for immunotherapy through enhancing arterial programming of hemogenic endothelium (HE). The anti-DLL4 blocking antibody was obtained from Creative Biolabs.

• Yamamoto, Mizuki, et al. "Cell–cell and virus–cell fusion assay–based analyses of alanine insertion mutants in the distal α9 portion of the JRFL gp41 subunit from HIV-1." Journal of Biological Chemistry 294.14 (2019): 5677-5687.

This paper suggests that the presence of a Q residue at position 644 in the distal α9 portion of the JRFL gp41 subunit of HIV-1 is critical for cell-cell membrane fusion. The anti-gp120 antibody PGT151 was obtained from Creative Biolabs.

• Guo, Zhiliang, Yuanyuan Liu, and Min Cheng. "Resveratrol protects bupivacaine-induced neuro-apoptosis in dorsal root ganglion neurons via activation on tropomyosin receptor kinase A." Biomedicine & Pharmacotherapy 103 (2018): 1545-1551.

This paper suggested that resveratrol may protect anesthesia-induced dorsal root ganglia (DRG) neuro-apoptosis, and activation of tropomyosin receptor kinase A (TrkA) signaling pathway may be the underlying mechanism in this process. The TrkA blocking antibody was obtained from Creative Biolabs.

• Gilbert, Brian E., et al. "Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge." Vaccine 36.52 (2018): 8069-8078.

The authors found respiratory syncytial virus (RSV) fusion (F) glycoprotein vaccine induced antibodies that bind to conserved epitopes; that use of adjuvant increased antibody avidity; and the polyclonal, high-avidity antibodies neutralized and protected against both wild-type and palivizumab-resistant mutant virus. The anti-RSV antibody (D25) was obtained from Creative Biolabs.

• Zhang, Hanlin, et al. "Polyamines control eIF5A hypusination, TFEB translation, and autophagy to reverse B cell senescence." Molecular cell 76.1 (2019): 110-125.

The results in this paper reveal an unexpected autophagy regulatory mechanism mediated by eIF5A at the translational level, which can be harnessed to reverse immune senescence in humans. The anti-hypusine antibody was obtained from Creative Biolabs.

• Ranallo, Simona, Daniela Sorrentino, and Francesco Ricci. "Orthogonal regulation of DNA nanostructure self-assembly and disassembly using antibodies." Nature communications 10.1 (2019): 1-9.

The authors demonstrated the ability to induce self-assembly and disassembly of two distinct DNA tubular structures by using DNA circuits controlled by two different IgG antibodies (anti-Dig and anti-DNP antibodies) in the same solution in an orthogonal way. This paper mentioned the anti-DNP Fab fragment was obtained from Creative Biolabs.

• Dong, Bohan, et al. "Different Triple-Negative Breast Cancer Tumor Cell Lysates (TCLs) Induce Discrepant Anti-Tumor Immunity by PD1/PDL-1 Interaction." Medical science monitor: international medical journal of experimental and clinical research 25 (2019): 500.

The results in this paper show that different contents of PDL-1 in tumor cell lysates (TCLs), by interacting with PD expression on lymphocytes, can induce different ratios of lymphocyte apoptosis, and then result in distinct response of the 4 TNBC cell lines to TCL-based immunotherapy. The anti-PD antibody was obtained from Creative Biolabs.

• Dukhovny, Anna, Amir Shlomai, and Ella H. Sklan. "The antiviral protein Viperin suppresses T7 promoter dependent RNA synthesis–possible implications for its antiviral activity." Scientific reports 8.1 (2018): 8100.

The results in this paper suggest a novel mechanism involving polymerase inhibition and provide a tractable system for future mechanistic studies of viperin. The anti-T7 polymerase antibody was obtained from Creative Biolabs.

• Lee, Youri, et al. "The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants." Antiviral research (2019).

This study demonstrates the efficacy of inactivated, detergent-split respiratory syncytial virus (RSV) as an effective vaccine candidate. The anti-RSV antibody (D25) was obtained from Creative Biolabs.

• Wang, Ying, et al. "Tumor-Contacted Neutrophils Promote Metastasis by a CD90-TIMP-1 Juxtacrine–Paracrine Loop." Clinical Cancer Research 25.6 (2019): 1957-1969.

The findings in this paper unravel a location-dictated interaction between tumor cells and neutrophils and provide a rationale for new anti-metastasis treatments. The anti-frizzled2 antibodies was obtained from Creative Biolabs.

SECTION 3: Single Domain Antibodies (SdAbs) [Top]

Creative Biolabs provides the most complete collection of sdAb products the world has ever had. From premade to immunized phage display library, our proprietary sdAb platform allows rapid generation and large-scale production of high affinity novel biological therapeutics that have potential in a wide range of human diseases.

• Singh, Sunanda, et al. "Suppression of Breast Cancer Cell Proliferation by Selective Single-Domain Antibody for Intracellular STAT3." Breast cancer: basic and clinical research 12 (2018): 1178223417750858.

This paper suggests that anti-signal transducer and activator of transcription 3 (STAT3) single-domain 15-kDa antibody SBT-100 can be developed for therapeutic intervention for cancer cells expressing STAT3 or p-STAT3. The VHHs against STAT3 was obtained from Creative Biolabs.

For research use only. Not intended for any clinical use.